NK010
Phase 1Biologic
NK010 is one of 52 biologic programs targeting Neoadjuvant Therapy. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
60 competitors in Neoadjuvant Therapy
#DrugCompanyPhaseTrials
1Lenvima
EisaiPhase 3
Tyvyt
Innovent Biologics (Suzhou) Co. Ltd.Phase 3
Tuoyi
CCoherus Oncology, Inc.
Phase 3
Keytruda
Merck & Co.Phase 2
Avastin
RochePhase 2
Beyfortus
BeiGenePhase 2
Abraxane
Bristol-Myers SquibbPhase 2
Tagrisso
AstraZenecaPhase 2
Eloxatin
TevaPhase 2
Ellence
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Neoadjuvant Therapy1 trial
NK-cell Therapy Combined With PD-1 Antibody and Platinum-Based Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC
Not yet recruiting·TThe First Affiliated Hospital of Guangzhou Medical University·Phase 1·NCT07318636·10 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NK010. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details